Literature DB >> 12098068

Human herpesvirus-6 encephalitis after unrelated umbilical cord blood transplant in children.

K W Chik1, P K S Chan, C K Li, M M K Shing, V Lee, A F Cheng, P M P Yuen.   

Abstract

Three children developed human herpesvirus-6 (HHV-6), variant B encephalitis after unrelated umbilical cord blood transplant, in a single center. They developed clinical manifestations of encephalitis around day 17 post transplant. Impairment of consciousness, incoherent speech, episodic focal pruritus, motor weakness, convulsions and severe hyponatremia were features at presentation. Radiological investigation of brain ranged from unremarkable to extensive white matter and meningeal lesions. Diagnosis was established by the presence of HHV-6 DNA in cerebrospinal fluid (CSF). Retrospective analyses of plasma revealed the presence of viral DNAemia prior to the onset of disease in two subjects. Treatment with ganciclovir or foscarnet was given. Two subjects did not achieve engraftment and died of other transplant-related complications on day 38 and 56 post-transplant, respectively. One subject achieved disease-free survival for more than 1 year with a satisfactory neurological outcome. In conclusion, HHV-6 encephalitis is not uncommon among patients undergoing umbilical cord blood transplantation. It is worth conducting further studies on early diagnosis and optimal management of this potentially fatal disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12098068     DOI: 10.1038/sj.bmt.1703596

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

Review 1.  Update on stem cell therapy for cerebral palsy.

Authors:  James E Carroll; Robert W Mays
Journal:  Expert Opin Biol Ther       Date:  2011-02-08       Impact factor: 4.388

2.  Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.

Authors:  Joshua A Hill; Sophia Koo; Belisa B Guzman Suarez; Vincent T Ho; Corey Cutler; John Koreth; Philippe Armand; Edwin P Alyea; Lindsey R Baden; Joseph H Antin; Robert J Soiffer; Francisco M Marty
Journal:  Biol Blood Marrow Transplant       Date:  2012-05-04       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.